Sponsor:
Merck Sharp & Dohme LLC
Code:
NCT06422143
Conditions
Non-small Cell Lung Cancer
NSCLC
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab
sac-TMT
Carboplatin
Paclitaxel
Nab-paclitaxel
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-27. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-12-04.